Sponsor Study ID:
A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on or Are Intolerant to a PD 1/L 1, EGFR, or ALK Inhibitor
To assess antitumor activity of BA3011 alone and in combination with nivolumab.
To assess the safety of BA3011 alone and in combination with nivolumab.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
(MUSC NetID required for document access)